```xml
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<ns3:query_definition xmlns:ns2="http://www.i2b2.org/xsd/cell/crc/psm/1.1/" xmlns:ns4="http://www.i2b2.org/xsd/cell/crc/psm/analysisdefinition/1.1/" xmlns:ns3="http://www.i2b2.org/xsd/cell/crc/psm/querydefinition/1.1/">
    <query_name>Prima-Immun-Metho@10:54:49</query_name>
    <query_timing>ANY</query_timing>
    <specificity_scale>0</specificity_scale>
    <panel>
        <panel_number>1</panel_number>
        <panel_timing>ANY</panel_timing>
        <panel_accuracy_scale>100</panel_accuracy_scale>
        <invert>0</invert>
        <total_item_occurrences>1</total_item_occurrences>
        <item>
            <hlevel>5</hlevel>
            <item_name>Primary central nervous system lymphoma</item_name>
            <item_key>\\ICD10_ICD9\Diagnoses\(C00-D49) Neop~k3n8\(C00-C96) Mali~yqqr\(C81-C96) Mali~u9p7\(C83) Non-foll~9ost\(200.5)Primary~7laf\</item_key>
            <item_icon>LI</item_icon>
            <tooltip>Diagnoses \ Neoplasms (c00-d49) \ Malignant neoplasms (c00-c96) \ Malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96) \ Non-follicular lymphoma \ Primary central nervous system lymphoma</tooltip>
            <class>ENC</class>
            <item_is_synonym>false</item_is_synonym>
        </item>
    </panel>
    <panel>
        <panel_number>2</panel_number>
        <panel_timing>ANY</panel_timing>
        <panel_accuracy_scale>100</panel_accuracy_scale>
        <invert>0</invert>
        <total_item_occurrences>1</total_item_occurrences>
        <item>
            <hlevel>4</hlevel>
            <item_name>Immunodeficiency following hereditary defective response to epstein-barr virus</item_name>
            <item_key>\\ICD10_ICD9\Diagnoses\(D50-D89) Dise~nx0c\(D80-D89) Cert~cp5q\(D82) Immunode~omxs\(D82.3) Immuno~b0nm\</item_key>
            <item_icon>LA</item_icon>
            <tooltip>Diagnoses \ Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (d50-d89)
 \ Certain disorders involving the immune mechanism (d80-d89) \ Immunodeficiency associated with other major defects \ Immunodeficiency following hereditary defective response to epstein-barr virus</tooltip>
            <class>ENC</class>
            <item_is_synonym>false</item_is_synonym>
        </item>
    </panel>
    <panel>
        <panel_number>3</panel_number>
        <panel_timing>ANY</panel_timing>
        <panel_accuracy_scale>100</panel_accuracy_scale>
        <invert>0</invert>
        <total_item_occurrences>1</total_item_occurrences>
        <item>
            <hlevel>4</hlevel>
            <item_name>Methotrexate</item_name>
            <item_key>\\i2b2_MEDS\i2b2\Medications\MUL\(LME55) antineoplastics\(LME58) antimetabolites\methotrexate\</item_key>
            <item_icon>FA</item_icon>
            <tooltip>medications \ antineoplastics \ antimetabolites \ methotrexate</tooltip>
            <class>ENC</class>
            <item_is_synonym>false</item_is_synonym>
        </item>
    </panel>
</ns3:query_definition>

```

I want to find patients with a diagnosis of primary central nervous system lymphoma and a history of immunodeficiency following hereditary defective response to Epstein-Barr virus, who have been prescribed methotrexate medication.